Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
复制标题
miR-181b 和 miR-21 在接受 S-1/奥沙利铂或多西氟尿苷/奥沙利铂治疗的胃癌患者中的预后意义
DOI：
10.1371/journal.pone.0023271
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Ju J
中科院分区：
文献类型：
--
作者：
Jiang J;Zheng X;Xu X;Zhou Q;Yan H;Zhang X;Lu B;Wu C;Ju J
本研究的目的是评价S-1/奥沙利铂与脱氧氟尿苷/奥沙利铂方案的有效性，并鉴定miRNA作为胃癌患者潜在的预后生物标志物。从55个晚期胃癌FFPE标本中定量候选miRNA的表达。实验设计招募KPS>70的胃癌患者进行试验。对照组接受400 mg/2次/天去氧氟尿苷联合奥沙利铂静脉给药，130 mg/m2/第1天/4周为1周期。试验组接受S-1 40 mg/2次/天/4周周期联合奥沙利铂130 mg/m2/第1天/4周周期静脉给药。从正常和胃肿瘤标本中提取总RNA。使用真实的时间qRT-PCR表达分析定量miRNA的水平。结果替吉奥/奥沙利铂治疗晚期胃癌的总有效率（CR+PR）为33.3%（CR+PR），去氧氟尿苷/奥沙利铂为17.6%（CR+PR）。接受S-1/奥沙利铂治疗的患者的平均总生存期为7.80个月，而接受去氧氟尿苷/奥沙利铂治疗的患者为7.30个月。胃癌组织中miR-181 b（P = 0.022）和miR-21（P =0.0029）的表达显著高于正常胃组织。 Kaplan-Meier生存分析显示，低水平的miR-21表达（对数秩检验，风险比：0.17，CI = 0.06-0.45; P = 0.0004）和miR-181 b（对数秩检验，风险比：0.37，CI = 0.16-0.87; P = 0.018）与基于S-1和脱氧氟尿苷的治疗方案的更好患者总生存期密切相关。 结论S-1/奥沙利铂联合化疗方案的疗效优于去氧氟尿苷/奥沙利铂方案。miR-21和miR-181 b作为晚期胃癌的预后生物标志物具有很大的潜力。
Background The goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs was quantified from fifty-five late stage gastric cancer FFPE specimens. Experimental Design Gastric cancer patients with KPS>70 were recruited for the trial. The control group was treated with 400 mg/twice/day Doxifluridine plus i.v. with Oxaliplatin at 130 mg/m2/first day/4 week cycle. The testing group was treated with S-1 at 40 mg/twice/day/4 week cycle plus i.v. with Oxaliplatin at 130 mg/m2/first day/4 week cycle. Total RNAs were extracted from normal and gastric tumor specimens. The levels of miRNAs were quantified using real time qRT-PCR expression analysis. Results The overall objective response rate (CR+PR) of patients treated with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6% (CR+PR) with Doxifluridine/Oxaliplatin for advanced stage gastric cancer patients. The average overall survival for patients treated with S-1/Oxaliplatin was 7.80 month vs. 7.30 month with patients treated with Doxifluridine/Oxaliplatin. The expression of miR-181b (P = 0.022) and miR-21 (P = 0.0029) was significantly overexpressed in gastric tumors compared to normal gastric tissues. Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard ratio: 0.17, CI = 0.06–0.45; P = 0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI = 0.16–0.87; P = 0.018) are closely associated with better patient's overall survival for both S-1 and Doxifluridine based regimens. Conclusion Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin. miR-21 and miR-181b hold great potential as prognostic biomarkers in late stage gastric cancer.
登录
查看更多内容
影响因子：
120.7
作者：
Schetter, Aaron J.;Leung, Suet Yi;Harris, Curtis C.
通讯作者：
Harris, Curtis C.
影响因子：
64.5
作者：
LEE, RC;FEINBAUM, RL;AMBROS, V
通讯作者：
AMBROS, V
影响因子：
56.9
作者：
Pillai, RS;Bhattacharyya, SN;Filipowicz, W
通讯作者：
Filipowicz, W
影响因子：
4.5
作者：
Xi, Yaguang;Nakajima, Go;Ju, Jingfang
通讯作者：
Ju, Jingfang
影响因子：
4
作者：
Park, David J.;Lenz, Heinz-Josef
通讯作者：
Lenz, Heinz-Josef